A groundbreaking antibody has been developed to combat the growth of drug-resistant breast cancers, providing a ray of hope for patients. This innovative treatment shows potential in addressing some of the most aggressive forms of the disease, according to experts.
The newly designed antibody offers a lifeline for patients who are unresponsive to current therapies, particularly those with triple-negative breast cancer, a subtype with limited treatment options. Scientists at King’s College London have engineered this antibody to not only target tumor cells directly but also activate the body’s immune defenses.
Described as a “triple-engineered antibody,” this novel approach involves the antibody binding to cancer cells while also attracting immune cells. The Breast Cancer Now Research Unit at King’s College London has been leading research efforts to enhance antibodies’ immune-stimulating properties for over a decade.
By manipulating the antibody’s structure, researchers found that it could effectively activate immune cells within tumors, curbing their growth in cases of triple-negative and treatment-resistant breast cancers. Additionally, the modified antibody demonstrated enhanced activation of immune cells in circulation, potentially bolstering the body’s ability to combat cancer.
Dr. Alicia Chenoweth, the lead author of the study, noted the antibody’s ability to activate immune cells more effectively than current treatments. The team’s findings suggest that the antibody can not only empower immune cells to eliminate cancer cells but also shift these cells to a more active state.
Professor Sophia Karagiannis, the study leader, highlighted the antibody’s unique approach in engaging key immune cell receptors within breast tumors, even those resistant to standard therapies. If successful, this novel therapy could directly stimulate the immune system and address the treatment gaps in resistant cancers like triple-negative breast cancer.
Triple-negative breast cancer, constituting 15% of all breast cancer cases, poses challenges due to its lack of hormone receptors targeted by conventional therapies. Dr. Simon Vincent of Breast Cancer Now expressed optimism about the potential impact of this research on improving treatment options for the over 8,000 women diagnosed with this aggressive form of breast cancer annually in the UK.
The team at King’s College is now advancing towards clinical trials to test immune-activating antibodies. Ongoing laboratory work aims to refine the therapy, extending the antibody’s efficacy and broadening its immune cell activation capabilities. Moreover, the researchers believe that this innovative therapy could hold promise for treating other cancers with shared antibody targets, such as ovarian and endometrial cancers.